Clinical Trial Update: Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in Adolescents [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the immunogenicity and safety of several rMenB Plus MenACWY vaccine formulations in adolescents has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease
• Meningococcal Meningitis

Drugs mentioned

• rMenB Plus MenACWY formulations

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Disease, Meningococcal Meningitis | Phase 2 | Status: COMPLETED